<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04860219</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-1937</org_study_id>
    <nct_id>NCT04860219</nct_id>
  </id_info>
  <brief_title>Lactoferrin Use in (SARS-CoV-2) Management</brief_title>
  <acronym>SARS-CoV-2</acronym>
  <official_title>The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS COV-2 Patients: A Randomized Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zagazig University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Preventive, adjunctive and curative properties of lactoferrin have been evaluated&#xD;
      since the first wave of severe acute respiratory syndrome coronavirus (SARS-CoV), viral&#xD;
      respiratory disease, emerged 18 years ago. Despite the discovery of new vaccine candidates,&#xD;
      there is currently no widely approved treatment for SARS-CoV-2 (COVID-19). Strict adherence&#xD;
      to infection prevention and control procedures, as well as vaccines, can, however, prevent&#xD;
      the spread of SARS-CoV-2. Objective: Hence, this study evaluated the efficacy of lactoferrin&#xD;
      treatment in improving clinical symptoms and laboratory indices among individuals with mild&#xD;
      to moderate coronavirus disease-19 (COVID-19). Design and Participants: A randomized,&#xD;
      prospective, interventional pilot study conducted between July 8 and September 18, 2020 used&#xD;
      a hospital-based sample of 54 laboratory confirmed participants with mild to moderate&#xD;
      symptoms of COVID-19. Randomization into a control and two treatment groups ensured all&#xD;
      groups received the approved Egyptian COVID-19 management protocol; only treatment group&#xD;
      participants received lactoferrin at different doses for seven days. Clinical symptoms and&#xD;
      laboratory indices were assessed on Days 0, 2 and 7 after starting treatments. Mean values&#xD;
      with standard deviation and one-way analysis of variance with least significant difference&#xD;
      post hoc of demographic and laboratory data between control and treatment groups were&#xD;
      calculated. Key Results: Our study showed no stastically significant difference among studied&#xD;
      groups regarding recovery of symptoms or laboratory improvement. Conclusion: Further research&#xD;
      into therapeutic properties particularly related to dosage, duration and follow-up after&#xD;
      treatment with lactoferrin in individuals with COVID-19 is required.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Actual">September 18, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to be symptoms free and normal laboratory results</measure>
    <time_frame>7 days after enrollment</time_frame>
    <description>duration from day 0 symptoms till 7 days symptoms free and normal laboratory findings</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>None of the participants in the Control Group received lactoferrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg lactoferrin orally once daily Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>received 200 mg lactoferrin orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg lactoferrin orally twice daily Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>received 200 mg lactoferrin orally twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactoferrin</intervention_name>
    <description>7 successive days treatment of Lactoferrin started within day 0 of COVID-19 diagnosis by RT-PCR</description>
    <arm_group_label>200 mg lactoferrin orally once daily Group</arm_group_label>
    <arm_group_label>200 mg lactoferrin orally twice daily Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. participants over 20 years of age&#xD;
&#xD;
          2. positive for nasopharyngeal swab reverse transcriptase polymerase chain reaction&#xD;
             (RT-PCR) for COVID-19&#xD;
&#xD;
          3. blood oxygen saturation (SpO2) &gt; 93%.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. pregnant and breastfeeding women&#xD;
&#xD;
          2. individuals confirmed to be allergic to milk protein&#xD;
&#xD;
          3. those with a medical history of bronchial hyperactivity or pre-existing respiratory&#xD;
             diseases&#xD;
&#xD;
          4. ICU inpatients with COVID-19.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>mohamed ghoniem, MD</last_name>
    <phone>00966540845657</phone>
    <email>teto2006.km@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine -Zagazig University</name>
      <address>
        <city>Zagazig</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mohamed ghoniem, MD</last_name>
      <phone>00966540845657</phone>
      <email>teto2006.km@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Mohamed E Ghoniem</investigator_full_name>
    <investigator_title>Associate Professor of Internal Medicine- Faculty of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactoferrin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The datasets generated and/or analyzed during the current study are available from the corresponding author upon request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

